Related references
Note: Only part of the references are listed.Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects
Bruno Fattizzo et al.
FRONTIERS IN ONCOLOGY (2020)
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment
Michael Hallek
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
K. Fischer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia
Zhijian Cao et al.
BLOOD (2019)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
Comorbidities Predict Inferior Outcomes in Chronic Lymphocytic Leukemia Treated With Ibrutinib
Max J. Gordon et al.
CANCER (2018)
Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force
R. Stauder et al.
ANNALS OF ONCOLOGY (2017)
Update of the Grupo Espanol de Leucemia Linfocitica Cronica clinical guidelines of the management of chronic lymphocytic leukemia
Jose A. Garcia-Marco et al.
MEDICINA CLINICA (2017)
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Paul M. Barr et al.
BLOOD (2017)
Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia
Martin Simkovic et al.
ARCHIVES OF MEDICAL SCIENCE (2016)
Clinical consequences of polypharmacy in elderly
Robert L. Maher et al.
EXPERT OPINION ON DRUG SAFETY (2014)
Chronic lymphocytic leukemia and autoimmunity: a systematic review
Kate Hodgson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Autoimmune Complications in Chronic Lymphocytic Leukaemia (CLL)
Clive S. Zent et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2010)
Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia
J. E. Castro et al.
LEUKEMIA (2009)
Management of autoimmune cytopenia complicating chronic lymphocytic leukemia
Clive S. Zent et al.
LEUKEMIA & LYMPHOMA (2009)
The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma
Clive S. Zent et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features
Deborah A. Bowen et al.
LEUKEMIA & LYMPHOMA (2007)
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features
FR Mauro et al.
BLOOD (2000)
Share Paper
